GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (FRA:LUP) » Definitions » 12-1 Month Momentum %

Luye Pharma Group (FRA:LUP) 12-1 Month Momentum % : -23.85% (As of Dec. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-13), Luye Pharma Group's 12-1 Month Momentum % is -23.85%.

The industry rank for Luye Pharma Group's 12-1 Month Momentum % or its related term are showing as below:

FRA:LUP's 12-1 Month Momentum % is ranked worse than
74.98% of 1063 companies
in the Drug Manufacturers industry
Industry Median: -2.52 vs FRA:LUP: -23.85

Competitive Comparison of Luye Pharma Group's 12-1 Month Momentum %

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luye Pharma Group's 12-1 Month Momentum % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's 12-1 Month Momentum % falls into.



Luye Pharma Group  (FRA:LUP) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Luye Pharma Group  (FRA:LUP) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Luye Pharma Group 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Luye Pharma Group Business Description

Traded in Other Exchanges
Address
Hongqiao Road 1438, 22/F, Gubei International Fortune Center II, Changning District, Shanghai, CHN, 264003
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, Cardiovascular system drugs, Alimentary tract and metabolism drugs and Central nervous system drugs. It derives maximum revenue from the sale of Oncology drugs.

Luye Pharma Group Headlines

No Headlines